Cyclacel Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2011 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Cyclacel Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2011 to Q4 2023.
  • Cyclacel Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $57.3M, a 7.54% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $57.3M +$4.02M +7.54% Dec 31, 2023 10-K 2024-03-21
Q4 2022 $53.3M -$3.39M -5.98% Dec 31, 2022 10-K 2024-03-21
Q4 2021 $56.7M +$14.6M +34.8% Dec 31, 2021 10-K/A 2023-11-29
Q4 2020 $42.1M +$4.69M +12.6% Dec 31, 2020 10-K 2022-03-30
Q4 2019 $37.4M +$1.94M +5.49% Dec 31, 2019 10-K 2021-03-01
Q4 2018 $35.4M -$9.46M -21.1% Dec 31, 2018 10-K 2020-03-05
Q4 2017 $44.9M -$4.49M -9.09% Dec 31, 2017 10-K 2019-03-28
Q4 2016 $49.4M +$2.02M +4.26% Dec 31, 2016 10-K 2018-03-30
Q4 2015 $47.4M -$4.19M -8.13% Dec 31, 2015 10-K 2017-03-31
Q4 2014 $51.5M -$4.96M -8.78% Dec 31, 2014 10-K 2016-03-29
Q4 2013 $56.5M +$6.29M +12.5% Dec 31, 2013 10-K 2015-03-31
Q4 2012 $50.2M -$579K -1.14% Dec 31, 2012 10-K 2014-03-26
Q4 2011 $50.8M Dec 31, 2011 10-K 2013-04-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.